Research Article
Development of Innovative Polymer-Based Matricial Nanostructures for Ritonavir Oral Administration
Figure 4
Size distribution of NPB-900 before (a) and after (b) interaction with mucin (NPB = nanoparticles without ritonavir).
| (a) |
| (b) |